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Purpose:To report an update of our previous experience using stereotactic body radiation
therapy (SBRT) for the primary treatment of prostate cancer, risk stratified by the updated
National Comprehensive Cancer Network (NCCN) version 2.2014, reporting efficacy and
toxicity in a community hospital setting.
Methods: From 2007 to 2012, 142 localized prostate cancer patients were treated with
SBRT using CyberKnife. NCCN guidelinesVersion 2.2014 risk groups analyzed included very
low (20%), low (23%), intermediate (35%), and high (22%) risk. To further explore group
heterogeneity and to comply with new guidelines, we separated our prior intermediate
risk group into favorable intermediate and unfavorable intermediate groups depending on
how many intermediate risk factors were present (one vs.>one). The unfavorable inter-
mediate group was further analyzed in combination with the high risk group as per NCCN
guidelines Version 2.2014. Various dose levels were used over the years of treatment, and
have been categorized into low dose (35 Gy, n=5 or 36.25 Gy, n=107) and high dose
(37.5 Gy, n= 30). All treatments were delivered in five fractions. Toxicity was assessed
using radiation therapy oncology group criteria.
Results: Five-year actuarial freedom from biochemical failure (FFBF) was 100, 91.7, 95.2,
90.0, and 86.7% for very low, low, intermediate and high risk patients, respectively. A
significant difference in 5 year FFBF was noted for patients with Gleason score (GS) ≥8
vs. 7 vs. 5/6 (p=0.03) and low vs. high dose (p=0.05). T-stage, pretreatment PSA, age,
risk stratification group, and use of ADT did not affect 5-year FFBF. Multivariate analysis
revealed GS and dose to be the most predictive factors for 5-year FFBF.
Conclusion: Our experience with SBRT for the primary treatment of localized prostate
cancer demonstrates favorable efficacy and toxicity comparable to the results reported
for IMRT in literature. GS remains the single most important pretreatment predictor of
outcome.
Keywords: stereotactic body radiation therapy, prostate cancer, CyberKnife, hypofractionation, NCCN guidelines,
risk stratification
INTRODUCTION
The American Society of Radiation Oncology (ASTRO) model
policy update of 2013 (1) acknowledged that stereotactic body
radiation therapy (SBRT) is equivalent to standard radiation
modalities used to treat prostate cancer such as intensity mod-
ulated radiation therapy (IMRT). In addition, the National
Comprehensive Cancer Network (NCCN) (2) “cautiously con-
siders SBRT as an alternative radiation treatment strategy to
conventional fractionated regimens at clinics with appropriate
technology, physics and clinical expertise” (p.707). For low and
intermediate risk prostate cancer, recent published literature
(3–6) supports these recommendations with excellent 5 year bio-
chemical control rates and correspondingly acceptable rates of
toxicity.
Prognostic factors necessary to guide staging and treatment
options for prostate cancer include Gleason score (GS), initial
PSA, and T-stage. These factors have been used to group patients
into risk categories of low, intermediate, and high risk, which
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correlate with outcome in radical prostatectomy and definitive
radiation series (7, 8). More recently, clinical criteria have been
introduced to predict pathologically “insignificant” prostate can-
cer, which is defined as clinical stage T1c, GS ≤6, disease in fewer
than 3 biopsy cores, and less than 50% involvement in any core
with PSA density <0.15 ng/mL/g (9–11). In addition, the Memo-
rial Sloane-Kettering group identified high-risk features within
the intermediate risk group, which correlated with decreased bio-
chemical freedom from relapse, decreased local control, increased
distant metastasis, and increased prostate-specific mortality. They
created stratifications of favorable and unfavorable intermediate
risk groups, assigning the unfavorable intermediate risk group to
patients with primary Gleason pattern of 4, percentage of biopsy
positive cores≥50%, or multiple NCCN-defined intermediate risk
factors (cT2b-c, PSA 10–20, or GS 7) (12).
The NCCN Prostate Cancer Panel recognized that heterogene-
ity exists within the previous risk stratification groups and has
redesigned guidelines for prostate cancer by risk categories, which
are linked to treatment paradigms with the hope that these updated
risk groups can be used more accurately to begin discussing treat-
ment options with prostate cancer patients. These updated NCCN
guidelines, version 2.2014, stratify prostate cancer into five risk
groups (very low, low, intermediate, high, and very high) utilizing
GS, initial PSA, and T-stage (2, 13). These guidelines separate out
“insignificant” very low risk prostate cancer and suggest raising
the risk group depending on number of risk factors within each
group. Clinical stage T2c is now considered intermediate risk by
NCCN (2) compared to the D’Amico classification, which places
T2c patients into the high risk category (7, 8).
We report an update of our previously published experi-
ence with CyberKnife SBRT (14), assessing efficacy and toxicity
while exploring the new NCCN risk groups in a consecutively
treated database of early stage prostate cancer. We have adopt
the Memorial group’s favorable and unfavorable intermediate risk
stratification but simplify the unfavorable intermediate group to
patients who demonstrate multiple NCCN-defined intermediate
risk factors to conform to the new NCCN guidelines.
MATERIALS AND METHODS
One hundred forty-two early stage prostate cancer patients
received SBRT at the Philadelphia CyberKnife Center from 2007
through 2012. The median and mean follow-up were 38 and
39 months, respectively, with a range of 0–76 months. This IRB-
approved retrospective study included updated information on 70
patients from our previous experience, in addition to 72 patients
treated thereafter. SBRT was delivered using the CyberKnife (Accu-
ray Inc., Sunnyvale, CA, USA) with MultiPlan inverse treatment
planning and motion tracking of internal fiducials. Treatment
planning began with transrectal or transperineal ultrasound-
guided placement of four gold fiducials into the prostate. A CT scan
(1.25-mm slice thickness) was obtained 10–14 days later to allow
inflammation to subside and to ensure fiducials did not migrate.
T2 weighted turbo spin-echo MRI was obtained for contouring the
prostate and seminal vesicles after registration by fiducials with CT
scan and T1 vibe fat suppression MRI.
The prostate, seminal vesicles, rectum, bladder, penile bulb,
testes, and sigmoid colon were contoured (Figure 1). Urethra
FIGURE 1 | CyberKnife SBRT treatment plan (36.25 Gy×5 fractions
prescribed to the 81% isodose line (white) with a 44.75 Gy maximum
dose). Shown are the prostate (43.6 cm3, red) and PTV (77.8 cm3, orange). A
bladder (green) volume of 1.66 cm3 received 37 Gy and 0.4 cm3 of the
rectum (yellow) received 36 Gy.
contouring was not required. The clinical target volume (CTV)
was the prostate for low risk patients and the prostate plus 2-cm
seminal vesicle base for intermediate/high risk patients. A total
dose of 35, 36.25, or 37.5 Gy, delivered in five fractions, was pre-
scribed to the planning target volume (PTV) that consisted of the
CTV with a 5 mm margin in all directions except 3 mm posteriorly.
Patients were typically treated over 8 days with a weekend off in
between with an every other day treatment schedule. If necessary
because of patient convenience or staff coverage, treatments were
consecutive. Our first cohort of patients was treated with 35 Gy
(n= 5) with subsequent dose escalation to 37.5 Gy (n= 30) per
department protocol and review of radiobiology data available at
the time. Most recent cohort was treated with a lower dose of
36.25 Gy (n= 107) after more published experience was available,
as well as participation in a national protocol, which required that
dose. The dose was not changed due to detected poor outcome or
toxicity. The dosimetric goal was to cover at least 95% of the PTV
with the prescribed dose normalized to the 75–85% isodose line
(dose heterogeneity 17–33%). Less than 1 cm3 of rectum received
36 Gy, 50% of the prescribed dose could not cross the posterior
rectal wall, and<10 cm3 of bladder received 37 Gy. Less than 50%
of the penile bulb received 29.5 Gy and less than 1 cc of the sig-
moid colon received 30 Gy. The average CTV and PTV were 56.9
(SD 26.1 cm3) and 98.3 cm3 (SD 38.6 cm3), respectively.
Orthogonal 120-kV X-ray image pairs were obtained through-
out treatment for use in motion tracking. The real-time prostate
position was locked-on by the relative fiducial position on the X-
rays. For those patients with evenly distributed fiducials in the
prostate quadrants, the prostate’s rotation was also tracked and
corrections were made in real time.
PSA nadir was defined as the lowest PSA value following
SBRT. Biochemical failure (BF) was assessed using the nadir+ 2
(Phoenix) definition. Toxicity was assessed using the radia-
tion therapy oncology group (RTOG) criteria; acute toxicity
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occurred within 3 months and late toxicity >3 months following
treatment (15).
Pretreatment factors were assessed for each patient, which
included standard risk factors of initial PSA, GS, and clinical stage.
Patients were stratified into four risk groups as per NCCN 2.2014
since we had only two very high risk patients who were included
with the high risk group. This stratification includes the NCCN
“very low” risk group designation, which separates our earlier low
risk group into two groups (very low and low). To explore group
heterogeneity, we separated our previous intermediate risk group
into favorable intermediate if there was one intermediate risk fac-
tor (Gleason 7 or clinical stage T2b/c or PSA> 10) or unfavorable
intermediate if there was more than one intermediate risk factor.
For the purpose of further analysis, the unfavorable intermediate
group was then combined with the high risk group as per NCCN
version 2.2014.
Kaplan–Meier estimates of freedom from biochemical failure
(FFBF) were used to describe the patients overall, and comparisons
were accomplished using log-rank statistics (16, 17). Simple Cox
proportional hazards regression modeling was used to estimate
hazard ratios for categorical variables of interest. The overall sam-
ple was described using measures of central tendency (mean and
median) and variation (standard deviation, IQR). Descriptive sta-
tistics were used to describe toxicity within each of the treatment
groups.
RESULTS
PATIENT AND TREATMENT CHARACTERISTICS
One hundred and forty-two consecutive patients were analyzed
with pretreatment and treatment factors described in Table 1.
NCCN risk groups are depicted in Table 1 with either three
(D’Amico classification) or five strata (NCCN version 2.2014
with intermediate risk group stratification and no high risk strat-
ification). Androgen deprivation therapy (ADT) in the form
of luteinizing hormone-releasing hormone agonist was used in
28.2% of patients (11.5% of the low risk, 37.7% of the intermediate
risk and 50% of the high risk). The use of ADT was dependent on
individual urologist and radiation oncologist preference. Selected
very low and low risk patients received ADT to shrink the prostate
before SBRT.
Patients who received 35 or 36.25 Gy were termed the“low-dose
group” and those who received 37.5 Gy the “high-dose group.”
Most patients (57%) received their treatment over 5–8 days. The
remainder completed treatment between 9 and 19 days with one
non-compliant patient receiving his final fraction several weeks
later, all due to poor adherence to their schedule. Treatment was
delivered with an average of 187 (SD= 26) non-coplanar beams.
X-ray images were taken every three to five beams to track the
prostate’s movement.
PSA RESPONSE AND BIOCHEMICAL CONTROL
The overall 5-year actuarial FFBF for the whole group was 92.7%
(Table 2). Six patients out of the entire cohort of 142 patients, all
in the low dose group, experienced BF; two were high risk, three
intermediate risk, and one low risk. The low-dose and high-dose
groups’ median PSA nadirs were 0.3 and 0.1 ng/mL, respectively.
Five year actuarial FFBF was 100% for the high dose group and
Table 1 | Patient and tumor characteristics.
Age at diagnosis Years
Median (IQR) 67 (61,73)
Range 44–88
Pretreatment PSA ng/mL
Mean (SD) 8.1 (7.7)
Median (IQR) 5.7 (4.4,8.3)
Pretreatment PSA Number of patients Percent
<10 ng/mL 115 81
10–20 ng/mL 19 13
>20 ng/mL 8 6
T-stage Number of patients Percent
T1c 106 75
T2a 19 13
>T2a 17 12
Gleason score Number of patients Percent
5–6 76 53
7 54 38
8+ 12 9
Risk Group (3) Number of patients Percent
Low 61 43
Intermediate 63 44
High 18 13
Risk group (5) Number of patients Percent
Very low 28 20
Low 33 23
Favorable intermediate 50 35
Unfavorable intermediate 13 9
High 18 13
Dose group Number of patients Percent
Low 112 79
High 30 21
Hormone treatment Number of patients Percent
No ADT 102 72
ADT 40 28
93.75% for the low dose group, p= 0.05, hazard ratio of 11.0 for
low compared to high dose (Table 2, Figure 2).
We analyzed the heterogeneity of intermediate risk prostate
cancer by stratifying into an intermediate favorable and unfavor-
able as described in the methods with a 5.2% decrement in 5-year
actuarial FFBF from 95.2 to 90.0%. We then compared the inter-
mediate unfavorable with high risk and found a 6.1% decrement
in 5-year actuarial FFBF from 90 to 83.9%. We then grouped the
intermediate unfavorable with the high risk group as per version
2.2014 NCCN guidelines with 5-year actuarial FFBF of 100% for
very low risk, 91.7% for low risk, 95.2% for intermediate risk,
and 86.7% for high risk (Table 2). Previous NCCN risk cate-
gories of low, intermediate, and high 5-year actuarial FFBF are
presented also in order to compare to other contemporary series
of prostate cancer SBRT (Table 2). Since there was little difference
in outcome in our data base between very low, low, and intermedi-
ate NCCN version 2.2014 risk categories, they were grouped and
compared to high risk with 5 year actuarial FFBF of 94.4% for
very low/low/intermediate and 86.7% for high (p= 0.07, Table 2).
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Table 2 | Freedom from biochemical failure stratified by risk and descriptive statistics.
1 year (%) 2 year (%) 3 year (%) 4 year (%) 5 year (%) P -value Hazard ratio
All patients 100.0 95.5 95.5 95.5 92.7
High risk 100.0 83.9 83.9 83.9 83.9 0.34 9.3
Intermediate unfavorable 100.0 90.0 90.0 90.0 90.0 6.8
Intermediate favorable 100.0 95.2 95.2 95.2 95.2 3.1
Low risk 100.0 100.0 100.0 100.0 91.7 2.4
Very low risk 100.0 100.0 100.0 100.0 100.0 1.0
High risk 100.0 83.9 83.9 83.9 83.9 0.14 7.0
Intermediate risk 100.0 94.2 94.2 94.2 94.2 2.5
Low risk 100.0 100.0 100.0 100.0 94.4 1.0
Combined risk groups High 100.0 86.7 86.7 86.7 86.7 0.07 4.0
Very low/low/intermediate 100.0 97.9 97.9 97.9 94.4 1.0
Pretreatment PSA <10 100.0 95.58 95.58 95.58 92.04 0.86 1.0
10–20 100.0 92.9 92.9 92.9 92.9 1.7
>20 100.0 100.0 100.0 100.0 100.0 1.8
T-stage T1c 100.0 97.8 97.8 97.8 94.2 0.19 1.0
T2a 100.0 85.7 85.7 85.7 85.7 4.7
Other (T2b+) 100.0 90.0 90.0 90.0 90.0 3.5
Gleason Score 5–6 100.0 100.0 100.0 100.0 95.5 0.03 1.0
7 100.0 93.4 93.4 93.4 93.4 3.5
8+ 100.0 76.2 76.2 76.2 76.2 12.5
Dose group Low 100.0 93.8 93.8 93.8 93.8 0.05 11.0
High 100.0 100.0 100.0 100.0 100.0 1.0
ADT No ADT 100.0 95.0 95.0 95.0 90.8 0.48 1.6
ADT 100.0 96.7 96.7 96.7 96.7 1.0
Bold font indicates significant p-value.
FIGURE 2 |Years of freedom from biochemical failure by dose for all patients.
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A statistically significant decrement in 5-year actuarial FFBF was
noted with increasing GS from 95.45 to 93.4% for GS 5/6 and 7
compared with 76.2% for GS≥ 8, p= 0.03, hazard ratio was 12.5
for GS≥ 8 vs. 3.5 for GS 7 vs. 1.0 for GS≤ 6 (Table 2, Figure 3).
Pretreatment PSA, T-stage, age, use of ADT, and risk stratification
groups were not significant with respect to 5-year FFBF.
Multivariate analysis evaluated the most significant factors in
univariate analysis including risk stratification groups, GS, and
dose. GS and dose were the most predictive factors in multivariate
analysis but did not reach statistical significance at the p< 0.05
level. Of note, with only six failures, we only have the power to
detect a single significant predictor of failure in the multivariate
analysis.
TOXICITY
Acute grade II GU toxicities were seen in 28% (n= 32/113) and
grade III GU toxicities were seen in 2% (n= 3/142). Two of the
three grade III acute GU toxicities manifested as frequency at least
every hour and the other experienced gross hematuria. The patient
who experienced gross hematuria had grade II baseline score with
multiple urinary tract infections and transurethral resection of the
prostate (TURP) prior to CyberKnife. All three patients’ toxicities
resolved within 3 months of treatment. However, one case of fre-
quency at least every hour reappeared as a late toxicity 6 months
after treatment. Acute gastrointestinal (GI) toxicity was limited to
4% (5/141) grade II toxicity with no acute grade III GI toxicity.
At most recent follow-up, persistent toxicities were limited to
grade II GU of 14% (18/132) and grade II GI of 3% (4/141). For
these persistent GI toxicities, there was no difference between dose
groups; however, for persistent grade II GU toxicities, the low dose
group observed less than the high dose group at 10 (10/102) and
27% (8/30), respectively. Of note there were three late grade III
GU toxicities 2% (n= 3/142), of which all three grade III patients
were in the high dose group. One patient with a 162 cm3 CTV
(the largest prostate in our patient sample) had acute grade III
frequency that resolved within 2 weeks of alpha-blocker and pro-
phylactic antibiotic treatment, but recurred 6 months later. His
symptoms improved to grade II immediately after TURP, which
was preformed 13 months after SBRT. Pathology of the resected
tissue was negative for tumor. The second patient with late grade
III GU toxicity experienced urinary retention. He had benign
prostate hypertrophy (BPH) and grade II symptoms at baseline.
At 14 months following SBRT, his symptoms progressed to grade
III then completely subsided following laser TURP. All three grade
III toxicities resolved at last follow to grade II or below.
Erectile dysfunction (ED) was assessed for the 48 patients who
were potent before SBRT and did not receive ADT. At last follow-
up, 13% lost the ability to achieve erections strong enough for
penetration and required ED medication for intercourse. Six per-
cent of patients who were potent before SBRT and did not receive
ADT developed ED refractory to medical treatment.
DISCUSSION
In this updated study, we double the original number of patients
and again report excellent FFBF rates with acceptable toxicity. The
observed FFBF rates are concordant with other published SBRT
outcomes for localized prostate cancer (Table 3) (3–5, 18).
To our knowledge, this is the first SBRT prostate cancer data
base reporting outcome stratified retrospectively by the new ver-
sion 2.2014 NCCN risk groups. In addition, we compare the
FIGURE 3 |Years of freedom from biochemical failure by Gleason score for all patients.
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Table 3 | SBRT publications for treatment of prostate cancer with 5 year actuarial %FFBF.
Study author Patient population Number of
patients
Dose Median follow-up
(months)
5-year %FFBF
Low Intermediate High
Freeman and King (5) Low risk only, 2 institutions 41 35Gy/5, 36.25Gy/5 60 93 – –
Kang et al. (18) 3 risk groups, single institution 44 32Gy/4, 34 Gy/4, 36Gy/4 40 100 100 91
King et al. (6) 3 risk groups, 8 institutions 1100 36.25Gy/4–5 36 95 84 81
Katz et al. (19) 3 risk groups, single institution 304 35Gy/5, 36.25Gy/5 60 97 91 74
Current study 3 risk groups, single institution 142 35Gy/5, 36.25Gy/5,
37.5Gy/5
38 94 94* 84
*Seven patients with T2c only included in intermediate group as per new NCCN guidelines.
prognostic value of other known factors in conjunction with
NCCN risk groups in univariate and multivariate analysis. The
current NCCN risk strategy separates out a very low risk group
using many pathologic features in addition to the classic factors
of low risk disease and separates out an unfavorable intermediate
risk group to be combined with the high risk group. Our data
suggest very little decrement in 5-year FFBF for very low, low, and
favorable intermediate groups until at least two intermediate risk
factors are present (unfavorable intermediate), which is grouped
with high risk in the version 2.2014 NCCN guidelines.
Our data also suggest that GS may be the most important
prognosticator being even more important than risk group strat-
ification. The hazard for GS 8 is over 12 fold than that of GS 5–6
and 9 fold than that of GS 7 in our series with p= 0.03. Katz et al.
observed a decrease in 5 year FFBF for patients within the inter-
mediate risk group with GS 4+ 3 vs. all others from 95 to 84% (4).
Katz et al. more recently reported their unfavorable intermediate
and high risk groups utilizing the NCCN version 2.2014 criteria.
Comparable to our series, only 47% of their high risk patients
received androgen deprivation with no difference in FFBF noted
in multivariate analysis. PSA was significant for outcome while GS
was not which differs from our series (19).
In our previous experience with 3-year actuarial FFBF rates, we
noted a statistically significant dose response for the intermediate
and high risk patients (14). In the current study, which includes
a larger sample size and longer follow-up, we continue to observe
a significant increase in 5-year FFBR between high and low dose
groups (p= 0.05). The sample size of the high dose group (n= 30)
is about one-fourth of the size of the low dose group; neverthe-
less, no BF occurred in the high-dose group despite the longer
median follow-up (57 vs. 33 months). This may come at the cost
of increased persistent late GU toxicity with 27% grade II toxici-
ties (compared to 10% in the low dose group). However, it is also
important to note that no grade III GU toxicities persist at most
recent follow-up.
A recently published multi-institutional consortium from eight
independent phase 2 studies has pooled together 1100 patients
with localized prostate cancer (3, 6). Patients had been treated
definitively with CyberKnife SBRT, having a median follow-up of
36 months and median dose of 36.25 Gy in 4–5 fractions. The risk
stratification consisted of 58% low risk, 30% intermediate risk,
and 11% high risk. They reported a 5-year FFBF 95, 84, and 81%,
respectively. Their overall 5-year FFBF rate was 93%, with 49 total
patients (4.9%) experienced failure. This experience parallels our
own, despite having a larger percentage of high and intermediate
risk patients in the current series. There was no observed dose
response among the range of doses used in the consortium of 35–
40 Gy. In addition to this analysis, they used a validated nomogram
to compare outcomes of SBRT to radical prostatectomy, exter-
nal beam radiotherapy, and permanent brachytherapy at 5 years.
Although our current study is retrospective, it is encouraging to
note these three conventional modalities have historically shown
FFBF rates comparable to CyberKnife SBRT in our study as well
as the aforementioned consortium of eight phase 2 studies.
Our late grade III urinary toxicity is similar to that reported in
the literature with no grade III GI toxicity (4, 5, 18–21). In our
experience, dose may increase this risk since all three patients in
our series with late grade III urinary toxicity were in the high dose
group of 37.5 Gy. This has been also reported by Katz et al. where
all patients in his series with grade III toxicity were in the 36.25 Gy
group compared with his 35 Gy group (4).
Radiation therapy oncology group 0938 is a randomized phase
II trial assessing hypofractionated regimens of 36.25 Gy in five
fractions of 7.25 Gy, and 51.6 Gy in 12 fractions of 4.3 Gy (22).
The patients in this protocol are favorable risk, and hypofraction-
ated schemes were delivered via linear accelerator, CyberKnife,
or proton therapy. The RTOG protocol included a fractionation
scheme (36.25 Gy in five fractions at 7.25 Gy), which was pre-
scribed for 75% of patients in our study. Although the patient
population in this protocol are all “favorable risk,” the primary
endpoint is first-year health-related quality of life (HRQOL) mea-
sured by Bowel and Urinary domains of the Expanded Prostate
Cancer Index Composite (EPIC) instrument; therefore, the results
will be meaningful from a toxicity standpoint and applicable to less
favorable risk patients (i.e., intermediate and high risk patients).
Favorable HRQOL and EPIC scores may further validate the dose
of 36.25 Gy in five fractions as the new standard. Fortunately, this
protocol met accrual goals and closed February 2014.
In conclusion, SBRT could be considered an appropriate alter-
native to other standard radiation treatment modalities for early
stage prostate cancer with excellent 5-year FFBF rates and low toxi-
city. Clinical expertise is required, but SBRT can be safely delivered
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in a community practice setting. The NCCN version 2.2014 fur-
ther refines the risk strata,which may help guide patients treatment
choices. GS may be the most important and simple prognostica-
tor for risk assessment. Further study is warranted for unfavorable
intermediate and high risk patients whose numbers are limited in
most SBRT series. The role of dose escalation is unclear due to
conflicting reports on the benefit on FFBF and risk of toxicity and
also warrants additional study.
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